Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Magnetic Implant Could Offer Improved Control Over Drug Delivery

XTALKS VITALS NEWS

Magnetic Implant

Researchers at the University of British Columbia (UBC) have developed Canada’s first magnetic drug implant as an alternative mode of drug delivery. Image courtesy of UBC.

Share this!

February 21, 2017 | by Sarah Hand, M.Sc.

Patients with a chronic disease often struggle to keep up with the numerous pills or intravenous injections required to manage their condition. Now, researchers at the University of British Columbia (UBC) have developed Canada’s first magnetic drug implant as an alternative mode of drug delivery.

The tiny medical device – just six millimeters in diameter – is composed of a silicone-based sponge impregnated with magnetic carbonyl iron particles. Drugs can be injected into the sponge layer, which is surrounded by a polymer, allowing it to be surgically implanted into the body.

The amount of drug released by the device is controlled by passing a magnet over the site of implantation. The magnet triggers the release of the drug from the spongey interior, which flows into the surrounding tissue through a small opening in the device.

“Drug implants can be safe and effective for treating many conditions, and magnetically controlled implants are particularly interesting because you can adjust the dose after implantation by using different magnet strengths,” said Ali Shademani, a PhD student in the biomedical engineering program at UBC. “Many other implants lack that feature.”



The device could be helpful for patients with diabetes, as the dosage of insulin is crucial to maintaining healthy blood sugar levels. The researchers published more details on the device in the journal, Advanced Functional Materials.

“This device lets you release the actual dose that the patient needs when they need it, and it’s sufficiently easy to use so that patients could administer their own medication one day without having to go to a hospital,” said John K. Jackson, a research scientist in UBC’s faculty of pharmaceutical sciences, and co-author of the study.

In testing the device, the researchers found that it was able to repeatedly deliver the drug every time the magnet was passed over the animal tissue. They also found that the effectiveness of the drug was not diminished despite being stored in the implanted device.

“This could one day be used for administering painkillers, hormones, chemotherapy drugs and other treatments for a wide range of health conditions,” said Mu Chiao, a professor of mechanical engineering at UBC, and senior author of the study. “In the next few years we hope to be able to test it for long-term use and for viability in living models.”


Keywords: Drug Delivery, Medical Implant, Dosage


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News


Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News


Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.